MedTrace Logo

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

NCT00310128 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-02-03

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as etoposide, methylprednisolone, cytarabine, and cisplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them without harming normal cells. Giving more than one drug (combination chemotherapy) together with rituximab and yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with rituximab and yttrium Y 90 ibritumomab tiuxetan works in treating patients with relapsed or refractory AIDS-related non-Hodgkin's lymphoma.

Conditions

  • AIDS-related Lymphoma
  • Adult Non-Hodgkin's Lymphoma
  • Anaplastic Large Cell Lymphoma

Interventions

DRUG

cisplatin

DRUG

cytarabine

DRUG

etoposide

DRUG

methylprednisolone

DRUG

rituximab

DRUG

yttrium Y 90 ibritumomab tiuxetan

PROCEDURE

antibody therapy

PROCEDURE

biological therapy

PROCEDURE

chemotherapy

PROCEDURE

monoclonal antibody therapy

PROCEDURE

radiation therapy

PROCEDURE

radioimmunotherapy

PROCEDURE

radioisotope therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • AIDS Malignancy Consortium

    lead NETWORK

Principal Investigators

  • Alexandra M. Levine, MD · University of Southern California

  • Anil Tulpule, MD · University of Southern California

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00310128 on ClinicalTrials.gov